The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Clinical stage drug development company Pharmaxis (PXS) has opened a $2 million share purchase plan (SPP) today after raising $7.2 million through a placement
  • The money will fund phase two trials using PXS-5505 to treat bone marrow and liver cancer
  • Pharmaxis is also progressing the PXS-6302 topical drug to phase 1C trial, which may improve the function and appearance of scarring
  • Shares in Pharmaxis closed at 10.5 cents today, the same price as the placement and SPP

Clinical stage drug development company Pharmaxis (PXS) has opened a $2 million share purchase plan (SPP) in the wake of raising $7.2 million through a placement.

The money will fund phase two trials: One using PXS-5505 to treat bone marrow cancer, the other using the same drug to treat liver cancer as a first-line treatment used in tandom with chemotherapy.

Pharmaxis CEO Gary Phillips said the placement was well supported and the SPP opens today.

“We hope there’ll be demand there to fill up the target of $2 million and that, together with the Placement, gives us the cash balance to make sure we can deliver both clinical trial results by the end of next year,” Mr Phillips said.

Pharmaxis is also progressing the PXS-6302 topical drug through to phase 1C trial.

It has the potential to improve the function and appearance of scarring.

Shares in the SPP will be issued at 10.5 cents each, in line with the placement, which represents a 12.4 per cent discount to the volume weighted average price of 11.98 cents on Friday, November 12.

Shares were trading on market at the same 10.5 cents at the close of today’s session.

PXS by the numbers
More From The Market Online

Week 17 Wrap: BHP-Anglo deal helps push down ASX; US data of concern but AI bulls happy

The big thematics and headlines that drove the ASX this week, plus, the headlines I think…
The Market Online Video

Market Close: ASX signs off on a sigh with all sectors red-lining

The ASX200 finished 1.3 per cent down with every sector in the red and Industrials and Real Estate brittle and bruised as bot…
The Market Online Video

Market Update: ASX on red alert with all sectors below the surface

The ASX200 is trading down around 1.1% with all eleven sectors in the red. Real-estate has…

ResMed spikes on robust results and global growth spurt

ResMed shares have climbed following the release of the company's strong Third Quarter FY2024 results.